Rapid Therapeutic Science Laboratories, Inc.
Rapid Therapeutic Science Laboratories, Inc. (RTSL): 3 pipeline candidates · ~40 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
39.7 months
D/E -1.76 · 0% dilution
Lead: Preclinical
3 candidates
N/A
N/A
A transparent, data-derived signal for Rapid Therapeutic Science Laboratories, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2K
Cash
$2K
Quarterly Burn
$7K
Runway
39.7 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| braide embolization assist device | — |
| comaneci | — |
| nhāler | Preclinical |
Frequently asked questions
How many drug candidates are in Rapid Therapeutic Science Laboratories, Inc.'s pipeline?
Rapid Therapeutic Science Laboratories, Inc. (RTSL) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Rapid Therapeutic Science Laboratories, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Rapid Therapeutic Science Laboratories, Inc. has approximately 39.7 months of cash runway.
What is Rapid Therapeutic Science Laboratories, Inc.'s market capitalization?
Rapid Therapeutic Science Laboratories, Inc.'s market capitalization is approximately $2K.
Who is the CEO of Rapid Therapeutic Science Laboratories, Inc.?
Mr. Donal R. Schmidt Jr. is the chief executive officer of Rapid Therapeutic Science Laboratories, Inc. (RTSL).
Get the full picture on Rapid Therapeutic Science Laboratories, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.